{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:08:39Z","timestamp":1789153719050,"version":"build-2803163510"},"reference-count":82,"publisher":"Society of Nuclear Medicine","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,8,18]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.2967\/jnumed.125.269527","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:16Z","timestamp":1789152016000},"page":"20S-29S","source":"Crossref","is-referenced-by-count":0,"title":["Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091111400906000_67.Supplement_2.20S.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026091111400906000_67.Supplement_2.20S.2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10661"},{"key":"2026091111400906000_67.Supplement_2.20S.3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00113"},{"key":"2026091111400906000_67.Supplement_2.20S.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2008.05.002"},{"key":"2026091111400906000_67.Supplement_2.20S.5","doi-asserted-by":"crossref","first-page":"105070","DOI":"10.1016\/j.phrs.2020.105070","article-title":"\u03b2-radiating radionuclides in cancer treatment, novel insight into promising approach","volume":"160","author":"Asadian","year":"2020","journal-title":"Pharmacol Res."},{"key":"2026091111400906000_67.Supplement_2.20S.6","doi-asserted-by":"publisher","DOI":"10.1667\/0033-7587(2000)153[0271:IDIASO]2.0.CO;2"},{"key":"2026091111400906000_67.Supplement_2.20S.7","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr230"},{"key":"2026091111400906000_67.Supplement_2.20S.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026091111400906000_67.Supplement_2.20S.9","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int."},{"key":"2026091111400906000_67.Supplement_2.20S.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026091111400906000_67.Supplement_2.20S.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026091111400906000_67.Supplement_2.20S.12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026091111400906000_67.Supplement_2.20S.14","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication [press release]. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Published March 28, 2025. Accessed September 5, 2025."},{"key":"2026091111400906000_67.Supplement_2.20S.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026091111400906000_67.Supplement_2.20S.16","doi-asserted-by":"crossref","unstructured":"Sartor O . Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Poster presented at: European Society of Medical Oncology Congress; 2024; Barcelona, Spain.","DOI":"10.1016\/j.annonc.2024.08.2308"},{"key":"2026091111400906000_67.Supplement_2.20S.17","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2023.41.16_suppl.5018","article-title":"Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T [abstract]","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06016-z"},{"key":"2026091111400906000_67.Supplement_2.20S.19","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.3390\/ijms25115667","article-title":"Preclinical evaluation of biodistribution and toxicity of [211At]PSMA-5 in mice and primates for the targeted alpha therapy against prostate cancer","volume":"25","author":"Watabe","year":"2024","journal-title":"Int J Mol Sci."},{"key":"2026091111400906000_67.Supplement_2.20S.20","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00259-024-07017-w","article-title":"First-in-human SPECT\/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer","volume":"52","author":"Watabe","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026091111400906000_67.Supplement_2.20S.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00184-7"},{"key":"2026091111400906000_67.Supplement_2.20S.22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/pros.23522","article-title":"Pharmacological upregulation of prostate\u2010specific membrane antigen (PSMA) expression in prostate cancer cells","volume":"78","author":"Kranzb\u00fchler","year":"2018","journal-title":"Prostate."},{"key":"2026091111400906000_67.Supplement_2.20S.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223099"},{"key":"2026091111400906000_67.Supplement_2.20S.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0342"},{"key":"2026091111400906000_67.Supplement_2.20S.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00400-w"},{"key":"2026091111400906000_67.Supplement_2.20S.26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9"},{"key":"2026091111400906000_67.Supplement_2.20S.28","first-page":"e546","article-title":"PSMAddition: phase 3 trial of [177Lu]Lu-PSMA-617 plus standard of care (SoC) vs. Soc alone in patients with metastatic hormone-sensitive prostate cancer [abstract]","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2026091111400906000_67.Supplement_2.20S.29","unstructured":"Novartis Pluvicto\u2122 demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer [press release]. Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-demonstrates-statistically-significant-and-clinically-meaningful-rpfs-benefit-patients-psma-positive-metastatic-hormone-sensitive-prostate-cancer. Published June 2, 2025. Accessed September 5, 2025."},{"key":"2026091111400906000_67.Supplement_2.20S.30","first-page":"252","article-title":"Targeting of osseous sites with \u03b1-emitting 223Ra: comparison with the \u03b2-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med."},{"key":"2026091111400906000_67.Supplement_2.20S.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"2026091111400906000_67.Supplement_2.20S.32","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","article-title":"LBA1: a randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3 [abstract]","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.33","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201507978"},{"key":"2026091111400906000_67.Supplement_2.20S.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.005"},{"key":"2026091111400906000_67.Supplement_2.20S.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6\\_suppl.017"},{"key":"2026091111400906000_67.Supplement_2.20S.36","doi-asserted-by":"publisher","DOI":"10.2307\/3579809"},{"key":"2026091111400906000_67.Supplement_2.20S.37","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.382"},{"key":"2026091111400906000_67.Supplement_2.20S.38","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0672"},{"key":"2026091111400906000_67.Supplement_2.20S.39","doi-asserted-by":"crossref","first-page":"103689","DOI":"10.1016\/j.dnarep.2024.103689","article-title":"DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor olaparib in BRCA1\/2 deficient tumors","volume":"139","author":"Wang","year":"2024","journal-title":"DNA Repair (Amst)."},{"key":"2026091111400906000_67.Supplement_2.20S.40","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1038\/s41598-020-67199-9","article-title":"Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP","volume":"10","author":"Cullinane","year":"2020","journal-title":"Sci Rep."},{"key":"2026091111400906000_67.Supplement_2.20S.41","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0868"},{"key":"2026091111400906000_67.Supplement_2.20S.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00535-5"},{"key":"2026091111400906000_67.Supplement_2.20S.44","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pros.24200","article-title":"DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells","volume":"81","author":"Chao","year":"2021","journal-title":"Prostate."},{"key":"2026091111400906000_67.Supplement_2.20S.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742"},{"key":"2026091111400906000_67.Supplement_2.20S.46","doi-asserted-by":"publisher","DOI":"10.1021\/bi00062a003"},{"key":"2026091111400906000_67.Supplement_2.20S.47","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0714"},{"key":"2026091111400906000_67.Supplement_2.20S.48","first-page":"12","article-title":"Combination of taxanes with radiation: preclinical studies","volume":"9","author":"Milas","year":"1999","journal-title":"Semin Radiat Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"2026091111400906000_67.Supplement_2.20S.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00646"},{"key":"2026091111400906000_67.Supplement_2.20S.51","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer."},{"key":"2026091111400906000_67.Supplement_2.20S.52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): a subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.53","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy141"},{"key":"2026091111400906000_67.Supplement_2.20S.54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7398"},{"key":"2026091111400906000_67.Supplement_2.20S.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1584"},{"key":"2026091111400906000_67.Supplement_2.20S.56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"2026091111400906000_67.Supplement_2.20S.57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2704"},{"key":"2026091111400906000_67.Supplement_2.20S.58","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2028"},{"key":"2026091111400906000_67.Supplement_2.20S.59","first-page":"S199","article-title":"The promise of targeted \u03b1-particle therapy","volume":"46","author":"Mulford","year":"2005","journal-title":"J Nucl Med."},{"key":"2026091111400906000_67.Supplement_2.20S.60","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.61","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) [abstract]","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.62","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1200\/JCO.2025.43.16_suppl.5016","article-title":"177Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001)","volume":"43","author":"Sandhu","year":"2025","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.63","doi-asserted-by":"crossref","first-page":"S968","DOI":"10.1016\/j.annonc.2024.08.1687","article-title":"1606P: mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591 [abstract]","volume":"35","author":"Holmes","year":"2024","journal-title":"Ann Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01600-6"},{"key":"2026091111400906000_67.Supplement_2.20S.65","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.2217\/fon-2022-0776","article-title":"KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer","volume":"18","author":"Gratzke","year":"2022","journal-title":"Future Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.66","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262017"},{"key":"2026091111400906000_67.Supplement_2.20S.67","doi-asserted-by":"publisher","DOI":"10.7150\/thno.56211"},{"key":"2026091111400906000_67.Supplement_2.20S.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04612-0"},{"key":"2026091111400906000_67.Supplement_2.20S.69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267206"},{"key":"2026091111400906000_67.Supplement_2.20S.70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050722"},{"key":"2026091111400906000_67.Supplement_2.20S.71","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266125"},{"key":"2026091111400906000_67.Supplement_2.20S.72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-6-107"},{"key":"2026091111400906000_67.Supplement_2.20S.73","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2020.38.15_suppl.5533","article-title":"Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer","volume":"38","author":"de Souza","year":"2020","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.74","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"2026091111400906000_67.Supplement_2.20S.75","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-23-3436","article-title":"A signal-finding study of abemaciclib in heavily pretreated patients with metastatic castration-resistant prostate cancer: results from CYCLONE 1","volume":"30","author":"Agarwal","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026091111400906000_67.Supplement_2.20S.76","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/JCO.2024.42.16_suppl.5001","article-title":"CYCLONE 2: a phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer","volume":"42","author":"Smith","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026091111400906000_67.Supplement_2.20S.77","doi-asserted-by":"publisher","DOI":"10.1155\/JBB.2005.287"},{"key":"2026091111400906000_67.Supplement_2.20S.78","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.7150\/thno.93249","article-title":"Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer: from bench to bedside","volume":"14","author":"Arbuznikova","year":"2024","journal-title":"Theranostics."},{"key":"2026091111400906000_67.Supplement_2.20S.79","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol."},{"key":"2026091111400906000_67.Supplement_2.20S.80","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263618"},{"key":"2026091111400906000_67.Supplement_2.20S.81","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268640"},{"key":"2026091111400906000_67.Supplement_2.20S.82","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.247197"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:40:45Z","timestamp":1789152045000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":82,"journal-issue":{"issue":"Supplement 2","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.2967\/jnumed.125.269527"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269527","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}